Paddler
Established Member
2021 paper
Abstract
A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses
Xueqiu Lin 1,6, Yanxia Liu 1,6,7, Augustine Chemparathy 1,2,6, Tara Pande 3, Marie La Russa 1,7, Lei S Qi 1,4,5,7,8,∗
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and variants has led to significant mortality. We recently reported that an RNA-targeting CRISPR-Cas13 system, called prophylactic antiviral CRISPR in human cells (PAC-MAN), offered an antiviral strategy against SARS-CoV-2 and influenza A virus.
Here, we expand in silico analysis to use PAC-MAN to target a broad spectrum of human- or livestock-infectious RNA viruses with high specificity, coverage, and predicted efficiency. Our analysis reveals that a minimal set of 14 CRISPR RNAs (crRNAs) is able to target >90% of human-infectious viruses across 10 RNA virus families. We predict that a set of 5 experimentally validated crRNAs can target new SARS-CoV-2 variant sequences with zero mismatches.
We also build an online resource (crispr-pacman.stanford.edu) to support community use of CRISPR-Cas13 for broad-spectrum RNA virus targeting. Our work provides a new bioinformatic resource for using CRISPR-Cas13 to target diverse RNA viruses to facilitate the development of CRISPR-based antivirals.
CRISPR/Cas13 could be used as broad anti viral for RNA viruses:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7985958/
https://www.genengnews.com/gen-edge...iosciences-uses-crispr-to-target-rna-viruses/
Dr Hanson and Dr Chia support the theory of chronic enterovirus non cytolytic infection as the driving mechanism in MECFS. This potential treatment would be worthy of consideration/investment.
Abstract
A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses
Xueqiu Lin 1,6, Yanxia Liu 1,6,7, Augustine Chemparathy 1,2,6, Tara Pande 3, Marie La Russa 1,7, Lei S Qi 1,4,5,7,8,∗
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and variants has led to significant mortality. We recently reported that an RNA-targeting CRISPR-Cas13 system, called prophylactic antiviral CRISPR in human cells (PAC-MAN), offered an antiviral strategy against SARS-CoV-2 and influenza A virus.
Here, we expand in silico analysis to use PAC-MAN to target a broad spectrum of human- or livestock-infectious RNA viruses with high specificity, coverage, and predicted efficiency. Our analysis reveals that a minimal set of 14 CRISPR RNAs (crRNAs) is able to target >90% of human-infectious viruses across 10 RNA virus families. We predict that a set of 5 experimentally validated crRNAs can target new SARS-CoV-2 variant sequences with zero mismatches.
We also build an online resource (crispr-pacman.stanford.edu) to support community use of CRISPR-Cas13 for broad-spectrum RNA virus targeting. Our work provides a new bioinformatic resource for using CRISPR-Cas13 to target diverse RNA viruses to facilitate the development of CRISPR-based antivirals.
CRISPR/Cas13 could be used as broad anti viral for RNA viruses:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7985958/
https://www.genengnews.com/gen-edge...iosciences-uses-crispr-to-target-rna-viruses/
Dr Hanson and Dr Chia support the theory of chronic enterovirus non cytolytic infection as the driving mechanism in MECFS. This potential treatment would be worthy of consideration/investment.
Last edited by a moderator: